Safety of sunitinib in patients with renal cell carcinoma following nephrectomy

被引：1
|
作者：
Heraudet, Luc [1 ]
Domblides, Charlotte [1 ,2 ]
Daste, Amaury [1 ]
Lefort, Felix [1 ]
Bernhard, Jean-Christophe [3 ]
Ravaud, Alain [1 ,2 ]
Gross-Goupil, Marine [1 ]
机构：
[1] Bordeaux Univ Hosp, Dept Med Oncol, St Andre, France
[2] Univ Bordeaux, Bordeaux, France
[3] Bordeaux Univ Hosp, Dept Urol, Bordeaux, France
来源：
EXPERT OPINION ON DRUG SAFETY | 2020年 / 19卷 / 07期
关键词：
Sunitinib; clear cell carcinoma; metastatic; safety; adjuvant; HIGH-RISK; ADJUVANT SUNITINIB; SORAFENIB; MANAGEMENT; THERAPY; HYPERTENSION; MALATE; ASSURE;
D O I：
10.1080/14740338.2020.1774551
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction The safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer. Areas covered In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either in the more recent adjuvant setting after nephrectomy or in the metastatic setting, with a focus on new data from the CARMENA and SURTIME trials. In particular, the aim was to determine the specificity of toxicity in the adjuvant setting. Expert opinion In the adjuvant setting, even if the toxicity profile of sunitinib does not differ significantly from that in the metastatic setting, the importance of the dose intensity and, thus, exposure has been emphasized. Consequently, as described mainly in the metastatic setting, management of the adverse effects of sunitinib remains critical.
引用
收藏
页码：799 / 806
页数：8
相关论文
共 50 条
  • [31] Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study
    Brunello, A.
    Basso, U.
    Sacco, C.
    Sava, T.
    De Vivo, R.
    Camerini, A.
    Barile, C.
    Roma, A.
    Maruzzo, M.
    Falci, C.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 336 - 342
  • [32] Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma
    Narayan, Vivek
    Keefe, Stephen
    Haas, Naomi
    Wang, Le
    Puzanov, Igor
    Putt, Mary
    Catino, Anna
    Fang, James
    Agarwal, Neeraj
    Hyman, David
    Smith, Amanda M.
    Finkelman, Brian S.
    Narayan, Hari K.
    Ewer, Steven
    ElAmm, Chantal
    Lenihan, Daniel
    Ky, Bonnie
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3601 - 3609
  • [33] Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
    Bottiglieri, Achille
    Sepe, Pierangela
    Stellato, Marco
    Pircher, Chiara
    Fotia, Giuseppe
    Leone, Alberto Giovanni
    Guadalupi, Valentina
    Claps, Melanie
    Giannatempo, Patrizia
    Verzoni, Elena
    Procopio, Giuseppe
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3071 - 3081
  • [34] Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma
    Bourlon, Maria T.
    Gao, Dexiang
    Trigero, Sara
    Clemons, Julia E.
    Breaker, Kathryn
    Lam, Elaine T.
    Flaig, Thomas W.
    CANCER MEDICINE, 2016, 5 (12): : 3386 - 3393
  • [35] Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma
    Singla, Nirmish
    Elias, Roy
    Ghandour, Rashed A.
    Freifeld, Yuval
    Bowman, Isaac A.
    Rapoport, Leonid
    Enikeev, Mikhail
    Lohrey, Jay
    Woldu, Solomon L.
    Gahan, Jeffrey C.
    Bagrodia, Aditya
    Brugarolas, James
    Hammers, Hans J.
    Margulis, Vitaly
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (12) : 924 - 931
  • [36] Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma
    Kato, Renpei
    Kato, Yoichiro
    Matsuura, Tomohiko
    Kanehira, Mitsugu
    Takata, Ryo
    Obara, Wataru
    BMC CANCER, 2017, 17 : 214
  • [37] Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules
    Atkinson, Bradley J.
    Kalra, Sarathi
    Wang, Xuemei
    Bathala, Tharakeswara
    Corn, Paul
    Tannir, Nizar M.
    Jonasch, Eric
    JOURNAL OF UROLOGY, 2014, 191 (03) : 611 - 618
  • [38] Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma
    Rautiola, Juhana
    Utriainen, Tapio
    Peltola, Katriina
    Joensuu, Heikki
    Bono, Petri
    ACTA ONCOLOGICA, 2014, 53 (01) : 113 - 118
  • [39] Do patients with metastatic renal cell carcinoma benefit from sunitinib?
    Wong, Bryan Y.
    Vogelzang, Nicholas J.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (02): : 72 - 73
  • [40] A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety
    Uemura, Hirotsugu
    Shinohara, Nobuo
    Yuasa, Takeshi
    Tomita, Yoshihiko
    Fujimoto, Hiroyuki
    Niwakawa, Masashi
    Mugiya, Soichi
    Miki, Tsuneharu
    Nonomura, Norio
    Takahashi, Masayuki
    Hasegawa, Yoshihiro
    Agata, Naoki
    Houk, Brett
    Naito, Seiji
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (03) : 194 - 202
12345